Compare · GRAL vs ILMN
GRAL vs ILMN
Side-by-side comparison of GRAIL Inc. (GRAL) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRAL and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.24B, about 9.1x GRAL ($3.12B).
- Over the past year, GRAL is up 106.2% and ILMN is up 94.2% - GRAL leads by 12.0 points.
- ILMN has been more active in the news (11 items in the past 4 weeks vs 10 for GRAL).
- ILMN has more recent analyst coverage (25 ratings vs 12 for GRAL).
- Company
- GRAIL Inc.
- Illumina Inc.
- Price
- $72.50+0.76%
- $186.76-1.85%
- Market cap
- $3.12B
- $28.24B
- 1M return
- +24.27%
- +13.80%
- 1Y return
- +106.20%
- +94.24%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 10
- 11
- Recent ratings
- 12
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest GRAL
- Director Chase William J was granted 276 shares, increasing direct ownership by 0.65% to 42,978 units (SEC Form 4)
- Director Summe Gregory L was granted 427 shares, increasing direct ownership by 0.94% to 45,672 units (SEC Form 4)
- Director Mizell Steven was granted 268 shares, increasing direct ownership by 0.63% to 42,830 units (SEC Form 4)
- Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans
- GRAIL Completes $110 Million Equity Financing With Samsung Entities
- Director Mizell Steven was granted 5,491 shares, increasing direct ownership by 15% to 42,562 units (SEC Form 4)
- Director Chase William J was granted 5,491 shares, increasing direct ownership by 15% to 42,702 units (SEC Form 4)
- Director Summe Gregory L was granted 5,491 shares, increasing direct ownership by 14% to 45,245 units (SEC Form 4)
- Director Krevans Sarah was granted 5,491 shares, increasing direct ownership by 15% to 42,628 units (SEC Form 4)
- GRAIL Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits